Building Your Child's Medical Team
At a Glance
Children with Fukuyama congenital muscular dystrophy need coordinated care from neuromuscular, neurologic, lung, heart, eye, and rehabilitation specialists. Keeping genetic, MRI, and CK records together and planning emergency breathing and anesthesia care helps teams respond safely.
Managing Fukuyama Congenital Muscular Dystrophy (FCMD) requires a team that looks at your child as a whole person, not just a set of symptoms. Because FCMD affects the muscles, brain, and eyes, you will need a multidisciplinary care team—a group of specialists who communicate with each other to synchronize your child’s care [1][2].
Your Core Medical Roster
The following specialists are typically essential for a child with FCMD:
- Neuromuscular Specialist: Usually a pediatric neurologist or a physical medicine and rehabilitation (PM&R) doctor with specific training in muscle diseases. They often act as the “quarterback” of the team, interpreting genetic tests and coordinating with other specialists [1].
- Pediatric Neurologist: While the neuromuscular specialist focuses on the muscles, a general pediatric neurologist is vital for managing the brain-related aspects of FCMD, such as developmental delays and seizures [3].
- Pulmonologist (Lung Specialist): They provide individualized respiratory assessment based on age, function, and symptoms [4]. They monitor for nocturnal hypoventilation (shallow breathing at night) and prescribe cough-assist or NIV machines [4].
- Cardiologist (Heart Specialist): Because FCMD can cause the heart muscle to weaken (cardiomyopathy) regardless of how strong the skeletal muscles are, your child will need a baseline echocardiogram and ECG, followed by regular monitoring based on their specific phenotype [5][6].
- Pediatric Ophthalmologist: FCMD can involve the eyes in ways that standard vision tests might miss. They will monitor for high myopia, involuntary eye movements (nystagmus), crossed eyes (strabismus), and specific changes to the retina or the optic nerve [7].
- Rehabilitation Team: This includes physical therapists (PT), occupational therapists (OT), and speech-language pathologists (SLP). They focus on maintaining joint flexibility, helping with communication, and ensuring swallowing is safe [6][8].
- Additional Team Members: Comprehensive care also requires a genetic counselor, dietitian, gastroenterologist, social worker, assistive-technology/AAC services, and palliative care for an extra layer of symptom and family support.
Vetting Your Care Team
Not every neurologist has experience with rare FKTN-related dystroglycanopathies. When meeting a new specialist, it is helpful to ask about their specific experience with FCMD. A qualified team should be familiar with the “founder mutation” and its specific risks, such as the late emergence of seizures or cardiac issues [3][5]. You may want to look for a center designated as a Muscular Dystrophy Association (MDA) Care Center or one that participates in congenital muscular dystrophy research registries [6][1].
Preparing for the First Major Visit
Specialists often need to see the “raw data” rather than just a summary letter. When building your team, prepare a folder (digital or physical) that includes:
- Genetic Test Results: Ensure you have the full laboratory report that mentions specific mutations like the SVA insertion or deep-intronic variants [6][7].
- Imaging: Bring the actual images (often on a CD or via a digital portal) for any Brain MRIs your child has had, so the team can look for patterns like cobblestone lissencephaly themselves [9].
- Lab History: A record of your child’s Creatine Kinase (CK) levels over time.
The Role of Coordination
The most effective teams have a designated care coordinator—often a nurse or social worker—who helps schedule appointments back-to-back. This reduces the “appointment fatigue” that families often feel [1].
Anesthesia Medical Alert: If your child needs surgery or sedation, ask your team to provide a medical-alert letter stating that sedation requires neuromuscular-experienced anesthesia and a preplanned respiratory and cardiac strategy [10].
Common questions in this guide
Which doctors and therapists should be part of my child's FCMD team?
How often will my child need heart and breathing tests?
What records should I bring to an FCMD appointment?
How do I find a medical center experienced with FCMD?
What will the eye specialist check in a child with FCMD?
Why is a care coordinator helpful for a child with FCMD?
What should be planned before surgery or sedation?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How many other children with FKTN-related dystroglycanopathies do you currently manage at this center?
- 2.Who will be the 'lead' coordinator for my child's care—the neuromuscular specialist, the neurologist, or someone else?
- 3.Does your center have a standard 'Emergency Respiratory Action Plan' that we can share with our local emergency room?
- 4.How frequently will my child need 'baseline' testing for their heart and lungs, and do you adjust that frequency based on their specific symptoms?
- 5.Since my child has FCMD, what specific findings will the pediatric ophthalmologist be looking for in the back of the eye?
- 6.If my child needs surgery or sedation, can you provide a medical-alert letter stating that anesthesia requires a neuromuscular specialist and pre-planned respiratory strategy?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (10)
- 1
Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.
Kang PB, Morrison L, Iannaccone ST, et al.
Neurology 2015; (84(13)):1369-78 doi:10.1212/WNL.0000000000001416.
PMID: 25825463 - 2
POMT1 and POMT2 gene mutations result in 2 cases of alpha-dystroglycanopathy.
Gan S, Yang H, Xiao T, et al.
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2021; (46(8)):915-919 doi:10.11817/j.issn.1672-7347.2021.200067.
PMID: 34565739 - 3
Epilepsy in patients with advanced Fukuyama congenital muscular dystrophy.
Kuwayama R, Suzuki Y, Nishikawa M, et al.
Brain & development 2021; (43(1)):106-110 doi:10.1016/j.braindev.2020.06.017.
PMID: 32723526 - 4
Respiratory management of patients with Fukuyama congenital muscular dystrophy.
Sato T, Murakami T, Ishiguro K, et al.
Brain & development 2016; (38(3)):324-30.
PMID: 26363734 - 5
Rapidly progressive heart failure requiring transplantation in muscular dystrophy: a need for frequent screening.
Pick JM, Ellis ZD, Alejos JC, Chang AC
Cardiology in the young 2017; (27(9)):1836-1840 doi:10.1017/S1047951117001251.
PMID: 28689515 - 6
National registry of patients with Fukuyama congenital muscular dystrophy in Japan.
Ishigaki K, Ihara C, Nakamura H, et al.
Neuromuscular disorders : NMD 2018; (28(10)):885-893 doi:10.1016/j.nmd.2018.08.001.
PMID: 30220444 - 7
Ophthalmologic manifestations associated with Fukutin (FKTN) variant subtypes in Korean patients with Fukuyama congenital muscular dystrophy: a single-center retrospective case series.
Lee SJ, Joo HJ, Jo DH, et al.
BMC ophthalmology 2025; (25(1)):616 doi:10.1186/s12886-025-04432-x.
PMID: 41188778 - 8
The gross motor function measure is valid for Fukuyama congenital muscular dystrophy.
Sato T, Adachi M, Nakamura K, et al.
Neuromuscular disorders : NMD 2017; (27(1)):45-49 doi:10.1016/j.nmd.2016.09.014.
PMID: 27818010 - 9
[Central Nervous Involvement in Patients with Fukuyama Congenital Muscular Dystrophy].
Ishigaki K
Brain and nerve = Shinkei kenkyu no shinpo 2016; (68(2)):119-27 doi:10.11477/mf.1416200361.
PMID: 26873231 - 10
Spinal correction in patients with Fukuyama congenital muscular dystrophy.
Saito W, Namba T, Inoue G, et al.
Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 2017; (22(4)):658-664 doi:10.1016/j.jos.2017.02.005.
PMID: 28325699
This page is for informational purposes only and does not constitute medical advice. Your child’s neuromuscular team should tailor testing, monitoring, emergency planning, and anesthesia recommendations to your child.
Get notified when new evidence is published on Congenital muscular dystrophy, Fukuyama type.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.